North America Clinical Trials Market Forecast to 2028

According to the research team research, the North America clinical trials market was valued at US$ 27,322.28 million in 2022 and is expected to reach US$ 36,818.15 million by 2028, registering a CAGR of 5.1% from 2022 to 2028. Increasing adoption and outsourcing of clinical trials and flourishing pharmaceutical industry and increasing R&D activities in pharmaceutical industry are the critical factors attributed to the North America clinical trials market expansion.

Clinical trials help determine if a new form of treatment or prevention, such as a new drug, diet, or medical device, is safe and effective. The trials are mainly carried out during drug development. According to the data provided by the National Library of Medicine (NLM), ~52,000 new studies were registered with NLM (ClinicalTrials.gov) in 2020, which increased to ~58,000 in 2023. In January 2023, the NLM reported 38,837 active clinical trials in the US and 105,172 active trials worldwide. An increasing number of clinical trials for developing different effective treatments due to the rising prevalence of chronic diseases is fueling the growth of the clinical trials market.

Further, clinical trials are increasingly becoming complex procedures, owing to which proper execution and overseeing of the operation occurring in research-based organizations has become crucial. To avoid errors due to improper execution, research-based organizations are outsourcing clinical trials to develop their products. Clinical research organizations (CROs) assist in successfully implementing clinical trials through the services offered using high-quality facilities and deep subject matter expertise. CROs have begun acting as a backbone of the clinical trial industry through their efficient and cost-effective operations benefitting trial sponsors. Thus, the development of cost-effective solutions and decreasing errors in CROs during the drug development process are driving the clinical trials market growth.

On the contrary, expensive and time-consuming process hurdles the growth of North America clinical trials market.

Based on phase, the North America clinical trials market is segmented into phase I, phase II, phase III, and phase IV. The phase III segment held 53.5% share of North America clinical trials market in 2022, amassing US$ 14,607.86 million. It is projected to garner US$ 19,943.61 million by 2028 to expand at 5.3% CAGR during 2022–2028.

Based on study design, the North America clinical trials market is segmented into interventional, observational, and expanded access. The interventional segment held 46.5% share of North America clinical trials market in 2022, amassing US$ 12,703.34 million. It is projected to garner US$ 17,384.01 million by 2028 to expand at 5.4% CAGR during 2022–2028.

Based on Indication, the North America clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, CNS condition, diabetes, obesity, cardiovascular, and others. The oncology segment held 28.5% share of North America clinical trials market in 2022, amassing US$ 7,789.51 million. It is projected to garner US$ 10,754.38 million by 2028 to expand at 5.5% CAGR during 2022–2028.

Based on country, the North America clinical trials market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 84.8% share of North America clinical trials market in 2022. It was assessed at US$ 23,161.09 million in 2022 and is likely to hit US$ 30,967.75 million by 2028, exhibiting a CAGR of 5.0% during 2022–2028.

Key players operating in the North America clinical trials market are Charles River Laboratories International Inc, ICON Plc, IQVIA Holdings Inc, IXICO Plc, Laboratory Corp of America Holdings, Parexel International Corp, SGS SA, Syneos Health Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd, among others.

In Feb 2023, Parexel launched a new expert series, New Medicines, Novel Insights. The series features fresh insights from the company’s global, cross-functional experts analyzing drug development trends and offering evidence-based guidance to the biopharmaceutical industry. In Feb 2022, IXICO next-generation brain imaging technology, which is more sensitive, accurate, and flexible than the current platform, will be available for clinical trials from March.

1. Introduction
1.1 Scope of the Study
1.2 The Research Team Report Guidance
1.3 Market Segmentation
1.3.1 North America Clinical Trials Market – By Phase
1.3.2 North America Clinical Trials Market – By Study Design
1.3.3 North America Clinical Trials Market – By Indication
1.3.4 North America Clinical Trials Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Clinical Trials Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.3 Experts Opinion
5. North America Clinical Trials Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Adoption and Outsourcing of Clinical Trials
5.1.2 Flourishing Pharmaceutical Industry and Increasing R&D Activities in Pharmaceutical Industry
5.2 Market Restraints
5.2.1 Expensive and Time-Consuming Process
5.3 Market Opportunities
5.3.1 Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials
5.4 Future Trends
5.4.1 AI-Driven Clinical Trials
5.5 Impact Analysis
6. Clinical Trials Market – North America Analysis
6.1 North America Clinical Trials Market Revenue Forecast and Analysis
7. North America Clinical Trials Market Revenue and Forecast To 2028 – by Study Design
7.1 Overview
7.2 North America Clinical Trials Market Revenue Share, by Study Design (2022 and 2028)
7.3 Interventional
7.3.1 Overview
7.3.2 Interventional: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Observational
7.4.1 Overview
7.4.2 Observational: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Expanded Access
7.5.1 Overview
7.5.2 Expanded Access: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8. North America Clinical Trials Market – By Phase
8.1 Overview
8.2 North America Clinical Trials Market, by Phase, 2022 and 2028 (%)
8.3 Phase III
8.3.1 Overview
8.3.2 Phase III: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Phase II
8.4.1 Overview
8.4.2 Phase II: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Phase IV
8.5.1 Overview
8.5.2 Phase IV: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Phase I
8.6.1 Overview
8.6.2 Phase I: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Clinical Trials Market Revenue and Forecast To 2028 – Indication
9.1 Overview
9.2 North America Clinical Trials Market Revenue Share, by Indication (2022 and 2028)
9.3 Autoimmune/Inflammation
9.3.1 Overview
9.3.2 Autoimmune/Inflammation: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Pain Management
9.4.1 Overview
9.4.2 Pain Management: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Oncology
9.5.1 Overview
9.5.2 Oncology: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.6 CNS Condition
9.6.1 Overview
9.6.2 CNS Condition: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.7 Diabetes
9.7.1 Overview
9.7.2 Diabetes: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.8 Obesity
9.8.1 Overview
9.8.2 Obesity: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.9 Cardiovascular
9.9.1 Overview
9.9.2 Cardiovascular: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.10 Other
9.10.1 Overview
9.10.2 Other: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10. North America Clinical Trials Market – Revenue and Forecast to 2028 – Country Analysis
10.1 North America: Clinical Trials Market
10.1.1 Overview
10.1.2 North America: Clinical Trials Market, by Country, 2022& 2028 (%)
10.1.2.1 US: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.1 Overview
10.1.2.1.2 US: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.3 US: Clinical Trials Market, by Phase, 2020-2028 (US$ Million)
10.1.2.1.4 US: Clinical Trials Market, by Study Design, 2020-2028 (US$ Million)
10.1.2.1.5 US: Clinical Trials Market, by Indication, 2020-2028 (US$ Million)
10.1.2.2 Canada: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.1 Overview
10.1.2.2.2 Canada: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.3 Canada: Clinical Trials Market, by Phase, 2020-2028 (US$ Million)
10.1.2.2.4 Canada: Clinical Trials Market, by Study Design, 2020-2028 (US$ Million)
10.1.2.2.5 Canada: Clinical Trials Market, by Indication, 2020-2028 (US$ Million)
10.1.2.3 Mexico: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.1 Overview
10.1.2.3.2 Mexico: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.3 Mexico: Clinical Trials Market, by Phase, 2020-2028 (US$ Million)
10.1.2.3.4 Mexico: Clinical Trials Market, by Study Design, 2020-2028 (US$ Million)
10.1.2.3.5 Mexico: Clinical Trials Market, by Indication, 2020-2028 (US$ Million)
11. Industry Landscape
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 IQVIA Holdings Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Parexel International Corp
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 IXICO Plc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Charles River Laboratories International Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 ICON Plc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 WuXi AppTec Co Ltd
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 SGS SA
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Syneos Health Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Thermo Fisher Scientific Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Laboratory Corp of America Holdings
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About Research Team
13.2 Glossary of Terms

Table 1. US Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 2. US Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 3. US Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 4. Canada: Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 5. Canada: Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 6. Canada: Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 7. Mexico: Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 8. Mexico: Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 9. Mexico: Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 10. Organic Developments Done by Companies
Table 11. Inorganic Developments Done by Companies
Table 12. Glossary of Terms

Figure 1. North America Clinical Trials Market Segmentation
Figure 2. North America Clinical Trials Market, By Country
Figure 3. North America Clinical Trials Market Overview
Figure 4. Phase III Segment Held Largest Share of Phase Segment in North America Clinical Trials Market
Figure 5. Canada is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. North America Experts Opinion
Figure 8. Impact Analysis
Figure 9. North America Clinical Trials Market– Revenue Forecast and Analysis – 2020- 2028
Figure 10. North America Clinical Trials Market Revenue Share, by Study Design (2022 and 2028)
Figure 11. Interventional: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Observational: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Expanded Access: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. North America Clinical Trials Market, by Phase 2022 and 2028 (%)
Figure 15. Phase III: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Phase II: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Phase IV: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Phase I: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. North America Clinical Trials Market Revenue Share, by Indication (2022 and 2028)
Figure 20. Autoimmune/Inflammation: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Pain Management: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Oncology: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. CNS Condition: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Diabetes: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Obesity: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Cardiovascular: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Other: North America Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. North America: Clinical Trials Market, by Key Country – Revenue (2022) (US$ Million)
Figure 29. North America: Clinical Trials Market, by Country, 2022 & 2028 (%)
Figure 30. US: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Canada: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Mexico: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Growth Strategies Done by the Companies in the Market, (%)